Please login to the form below

Not currently logged in
Email:
Password:

Roche's pertuzumab potential major advance in breast cancer

Adding drug to regimen of Herceptin and docetaxel sees significant progression-free survival in phase III trial

Adding Roche's pertuzumab to a regimen of Herceptin and docetaxel in patients with HER2-positive breast cancer has significantly improved progression-free survival in a phase III trial.

Updated results from the CLEOPATRA study were presented yesterday at the San Antonio Breast Cancer Symposium yesterday, and shortly after being published online in the New England Journal of Medicine.

The data revealed that the combination of pertuzumab, Herceptin (trastuzumab) and docetaxel was associated with progression-free survival of 18.4 months, compared to 12.4 months from Herceptin and docetaxel alone, a 38 per cent improvement.

The objective response rate in the trial was 80.2 per cent for patients receiving the triple combination and 69.3 per cent in the Herceptin and docetaxel group. Meanwhile, pertuzumab also seemed to be well-tolerated, with no increase in cardiovascular side effects compared to the comparator therapy.

While Herceptin was a major advance in HER2-positive breast cancer - and a spectacular success for Roche with sales of $6.8bn last year - most cases of advanced disease eventually progress despite treatment with the drug.

For that reason there has been considerable excitement over the potential of pertuzumab because it targets HER2 in a different and complementary way to Herceptin.

There are preliminary signs in CLEOPATRA that this optimism may be well-founded. Specifically, there was a trend towards improved overall survival with pertuzumab which, if confirmed in additional follow-up, could represent a significant advance over current therapy. Those data are due in 2013.

"These results show we may soon improve on the current standard of care, Herceptin plus chemotherapy, to further help people with this advanced form of the disease," said Hal Barron, Roche's chief medical officer and head of global product development.

Analysts have suggested that if pertuzumab can fulfil its potential in HER2-positive breast cancer it could achieve sales of around $2bn, helping to support Roche's oncology franchise when Herceptin starts to lose patent protection in 2015.

9th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics